Cancer Genomic Medicine in Japan: Current Status and Future Perspectives

Cancer genomic medicine (CGM) encompasses the integration of tumor genomic information into clinical decision-making. In Japan, comprehensive genomic profiling (CGP) is an essential component of CGM, as it facilitates the identification of actionable alterations, clinical trial enrollment, and treatment selection. Following the initiation of national insurance coverage in 2019, Japan has established a nationwide CGM network. However, clinical implementation remains limited by institutional restrictions, such as delayed testing and insufficient access to matched therapies. Recent evidence from CGP-guided therapies and expanding tumor-agnostic approvals, including those for trastuzumab deruxtecan for human epidermal growth factor receptor 2 (HER2)- positive solid tumors and alectinib for anaplastic lymphoma kinase (ALK) fusion-positive solid tumors, underscores the growing therapeutic relevance of molecular profiling and is expected to further accelerate precision oncology. This review summarizes recent advances in CGM that enable treatment selection based on molecular alterations beyond conventional tumor type-based approaches and discusses future directions considering the current healthcare system and challenges in Japan.

Authors

Institutions

Publication Details

Journal
Internal Medicine
Published
2026-11-19
DOI
https://doi.org/10.2169/internalmedicine.8246-26
Primary Topic
Cancer Genomics and Diagnostics
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Cancer Genomic Medicine in Japan: Current Status and Future Perspectives

Masayuki Takeda, Rika Sasaki
Internal Medicine
Cancer Genomics and Diagnostics
article

Cancer Genomic Medicine in Japan: Current Status and Future Perspectives

Masayuki Takeda, Rika Sasaki
article en

Abstract

Cancer genomic medicine (CGM) encompasses the integration of tumor genomic information into clinical decision-making. In Japan, comprehensive genomic profiling (CGP) is an essential component of CGM, as it facilitates the identification of actionable alterations, clinical trial enrollment, and treatment selection. Following the initiation of national insurance coverage in 2019, Japan has established a nationwide CGM network. However, clinical implementation remains limited by institutional restrictions, such as delayed testing and insufficient access to matched therapies. Recent evidence from CGP-guided therapies and expanding tumor-agnostic approvals, including those for trastuzumab deruxtecan for human epidermal growth factor receptor 2 (HER2)- positive solid tumors and alectinib for anaplastic lymphoma kinase (ALK) fusion-positive solid tumors, underscores the growing therapeutic relevance of molecular profiling and is expected to further accelerate precision oncology. This review summarizes recent advances in CGM that enable treatment selection based on molecular alterations beyond conventional tumor type-based approaches and discusses future directions considering the current healthcare system and challenges in Japan.

Internal Medicine
Nara Medical University (JP)
Good health and well-being
Cancer Genomics and Diagnostics
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon